Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
January 3, 2019
InflaRx Continues U.S. Expansion with Addition of New York City Corporate Office and Addition of Management
JENA, Germany and NEW YORK, Jan. 03, 2019 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company developing innovative therapeutics to treat devastating inflammatory diseases ...
January 3, 2019
OSE Immunotherapeutics to present at Biotech Showcase™ 2019 Conference
NANTES, France, Jan. 03, 2019 (GLOBE NEWSWIRE) --  OSE Immunotherapeutics(ISIN: FR0012127173; Mnémo: OSE), today announced that Alexis Peyroles, CEO, will present an overview of the ...
January 3, 2019
Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs in oncology, in ...
January 2, 2019
Acer Therapeutics Announces In-license of Osanetant from Sanofi
NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
January 2, 2019
AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer
GARDEN CITY, N.Y. and REHOVOT, Israel, Jan. 02, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on ...
January 2, 2019
BioLineRx to Present at the 2019 Biotech Showcase
BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that management will provide a corporate update at the 2019 ...
January 2, 2019
Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement
CRANBURY, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”) today announced that it closed on the third tranche (of four) ...
January 2, 2019
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
BOSTON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics, today announced ...
January 2, 2019
Orchard Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on January 9, 2019
BOSTON and LONDON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Orchard Therapeutics (ORTX), a leading commercial-stage biopharmaceutical company dedicated to transforming the lives of patients with ...
January 2, 2019
Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
EMERYVILLE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
December 20, 2018
iCAD, Inc. Announces $7.0 Million Private Placement of Unsecured Subordinated Convertible Debentures
NASHUA, N.H., Dec. 20, 2018 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a  global medical technology company providing innovative cancer detection and therapy solutions, today announced ...
December 20, 2018
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, ...
December 20, 2018
Lipocine Announces LPCN 1144 MRI-PDFF Clinical Results Selected for Presentation at Keystone Symposia on Integrated Pathways of Disease in NASH and NAFLD
SALT LAKE CITY, Dec. 20, 2018 /PRNewswire/ -- Lipocine Inc.(LPCN), a specialty pharmaceutical company, announced today that it has been selected to present LPCN 1144 clinical ...
December 20, 2018
Mustang Bio Receives Orphan Drug Designation for MB-102 (CD123 CAR T) for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
NEW YORK, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (MBIO), a company focused on the development of novel immunotherapies based on proprietary ...
December 20, 2018
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
Transgene (TNG.PA), a biotechnology company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that the primary endpoint (safety and tolerability) was met ...
December 19, 2018
Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
CUPERTINO, Calif., Dec. 19, 2018 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that Indivior PLC (INDV.L) stated on December 18, 2018 that it is moving ahead with ...
December 19, 2018
Aimmune Therapeutics Initiates Phase 3 POSEIDON Trial for Treatment of Peanut Allergy in 1–3-Year-Old Children
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it has initiated POSEIDON (Peanut ...
December 19, 2018
Eiger Announces Breakthrough Therapy Designation Granted by FDA for Lonafarnib in Progeria and Progeroid Laminopathies
PALO ALTO, Calif., Dec. 19, 2018 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (EIGR), focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases, ...
December 19, 2018
Krystal Biotech Completes Dosing in the GEM-Phase 2 Study in Pediatric Patients for the Treatment of Dystrophic Epidermolysis Bullosa
PITTSBURGH, Dec. 19, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological ...
December 19, 2018
AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients
NEW YORK, Dec. 19, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant therapies ...
Page 20 of 138